Johnson & Johnson (NYSE:JNJ) agreed on Friday to acquire Shockwave Medical Inc (NASDAQ:SWAV) for $335 per share in cash, corresponding to an enterprise value of approximately $13.1 billion, including cash acquired.  The acquisition of Shockwave Medical further extended Johnson & Johnson MedTech’s position in cardiovascular intervention and accelerated its shift into higher-growth markets.  Assuming the Shockwave deal is completed, Johnson & Johnson would have deployed approximately $30 billion over the past ~18 months in M&A to strengthen its MedTech portfolio, which accounted for around 35% of sales).  Goldman Sachs wrote that the acquisition of Shockwave signifies a strategic move in its efforts to revamp Johnson & Johnson’s MedTech division, which had been experiencing modest ...